Jazz Pharmaceuticals gets EU nod for Ziihera

6 days ago 2

Jazz Pharmaceuticals (NASDAQ:JAZZ) said on Tuesday that the European Commission has granted conditional marketing authorization for its antibody therapy, Ziihera, as a monotherapy for the treatment of biliary tract cancer.
The approval is specifically for adults with advanced biliary tract

Recommended For You